SETP17

Across TCGA pan-cancer cohorts, SETP17 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SETP17’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SETP17 RNA is repressed in tumor relative to normal tissue. In most cancer types SETP17 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

THCA, BRCA, and BLCA are the cancer types where SETP17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SETP17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.176	<.001	7	view →
BRCA	All	III,IV	−0.222	<.001	6	view →
BLCA	Male	IV	−0.347	.004	5	view →
LUAD	All	All	−0.204	<.001	5	view →
COAD	All	III,IV	−0.172	.001	5	view →
LUSC	Male	All	−0.203	<.001	4	view →
KIRC	Male	All	+0.125	<.001	4	view →
KIRP	All	II,III,IV	−0.124	.004	4	view →
LIHC	All	All	+0.082	.003	4	view →
UCEC	All	All	−0.183	.011	2	view →
LUSC	Female	III,IV	+0.320	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 10 lineages.

SETP17–THCA

Open the THCA breakdown →